-
Reply to: “Increase in HDV replication during steroid therapy – potential implications for testing and treatment strategies” J. Hepatol. (IF 25.7) Pub Date : 2024-04-04 Gabriele Ricco, Maurizia R. Brunetto
-
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment J. Hepatol. (IF 25.7) Pub Date : 2024-04-01 Stephen L. Chan, Baek-Yeol Ryoo, Frankie Mo, Landon L. Chan, Jaekyung Cheon, Leung Li, Kwan H. Wong, Nicole Yim, Hyeyeong Kim, Changhoon Yoo
-
Reply to: Comments on “An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis” J. Hepatol. (IF 25.7) Pub Date : 2024-03-28 Romée J.A.L.M. Snijders, Anna E.C. Stoelinga, Bart van Hoek, Joost P.H. Drenth
-
Reply to: “Distinction of autoimmune hepatitis from drug-induced autoimmune like hepatitis: The answer lies at the interface” J. Hepatol. (IF 25.7) Pub Date : 2024-03-28 Einar S. Björnsson, M Isabel Lucena, Raul J. Andrade
-
Planar cell polarity is crucial for proper morphogenesis of the bile ducts J. Hepatol. (IF 25.7) Pub Date : 2024-03-26 Frédéric P. Lemaigre
-
Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting J. Hepatol. (IF 25.7) Pub Date : 2024-03-26 Mitra K. Nadim, John A. Kellum, Lui Forni, Claire Francoz, Sumeet K. Asrani, Marlies Ostermann, Andrew S. Allegretti, Javier A. Neyra, Jody C. Olson, Salvatore Piano, Lisa B. VanWagner, Elizabeth C. Verna, Ayse Akcan-Arikan, Paolo Angeli, Justin M. Belcher, Scott W. Biggins, Akash Deep, Guadalupe Garcia-Tsao, Yuri S. Genyk, Pere Gines, Patrick S. Kamath, Sandra L. Kane-Gill, Manish Kaushik, Nuttha
Patients with cirrhosis are prone to developing acute kidney injury (AKI), a complication associated with a markedly increased in-hospital morbidity and mortality, along with a risk of progression to chronic kidney disease. Whereas patients with cirrhosis are at increased risk of developing any phenotype of AKI, hepatorenal syndrome (HRS), a specific form of AKI (HRS-AKI) in patients with advanced
-
Developing and validating clinical prediction models in hepatology – An overview for clinicians J. Hepatol. (IF 25.7) Pub Date : 2024-03-24 Rickard Strandberg, Peter Jepsen, Hannes Hagström
Prediction models are everywhere in clinical medicine. We use them to assign a diagnosis or a prognosis, and there have been continuous efforts to develop better prediction models. It is important to understand the fundamentals of prediction modelling, thus, we herein describe nine steps to develop and validate a clinical prediction model with the intention of implementing it in clinical practice:
-
Unraveling the liver antiviral immunity in functional cure of chronic hepatitis B using scRNAseq J. Hepatol. (IF 25.7) Pub Date : 2024-03-19 Pierre Tonnerre, Thomas F. Baumert
-
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-03-19 Lixia Xu, Ying Zhang, Zhilong Lin, Xinlang Deng, Xiaoxue Ren, Mingle Huang, Shangru Li, Qianying Zhou, Fei Fang, Qingxia Yang, Gaomin Zheng, Zebin Chen, Zhongdao Wu, Xi Sun, Jie Lin, Jingxian Shen, Jianping Guo, Xiaoxing Li, Tianchen Xue, Jing Tan, Xiaoxuan Lin, Li Tan, Hong Peng, Shunli Shen, Sui Peng, Shaoqiang Li, Lijian Liang, James M. Cleary, Jiaming Lai, Yubin Xie, Ming Kuang
-
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-03-18 Chittampalli N. Yashaswini, Tianyue Qin, Dipankar Bhattacharya, Corina Amor, Scott Lowe, Amaia Lujambio, Shuang Wang, Scott L. Friedman
-
Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy? J. Hepatol. (IF 25.7) Pub Date : 2024-03-16 Mark Thursz, Philippe Mathurin
-
Reply to: “irLI or not irLI: That is the question” J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Ciro Celsa, Giuseppe Cabibbo, David James Pinato
-
Expanding the Dialogue: A Closer Look at AIH Management and HCC Risk J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Dan Shan PhD
-
The MAFLD and MASLD conundrum: Is it reinvention of the wheel? J. Hepatol. (IF 25.7) Pub Date : 2024-03-13 Mariana M. Ramírez-Mejía, Mohammed Eslam, Nahum Méndez-Sánchez
-
Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Ann Thu Ma, Cristina Solé, Adrià Juanola, Laia Escudé, Laura Napoleone, Emma Avitabile, Martina Pérez-Guasch, Marta Carol, Enrico Pompili, Jordi Gratacós-Ginés, Anna Soria, Ana Belén Rubio, Marta Cervera, Maria José Moreta, Manuel Morales-Ruiz, Elsa Solà, Esteban Poch, Núria Fabrellas, Isabel Graupera, Elisa Pose, Pere Ginès
-
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Mathias Jachs, Lisa Sandmann, Lukas Hartl, Tammo Tergast, Michael Schwarz, David Josef Maria Bauer, Lorenz Balcar, Alena Ehrenbauer, Benedikt Silvester Hofer, Markus Cornberg, Henrike Lenzen, Katja Deterding, Michael Trauner, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy
-
One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Jubi de Haan, Fabian Termorshuizen, Nicolette de Keizer, Diederik Gommers, Caroline den Hoed
-
Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study J. Hepatol. (IF 25.7) Pub Date : 2024-03-11 Seo Hee Choi, Byung min Lee, Jina Kim, Do Young Kim, Jinsil Seong
Stereotactic ablative radiotherapy (SABR) has demonstrated curative potential with survival benefits in patients with oligometastatic disease (OMD). However, limited evidence exists regarding its use in oligometastatic hepatocellular carcinoma (HCC). We aimed to prospectively investigate the efficacy and safety of SABR in patients with oligometastatic HCC. We enrolled patients with controlled primary
-
Democratising the scientific method J. Hepatol. (IF 25.7) Pub Date : 2024-03-08 Shivaram Prasad Singh, Prajna Anirvan
-
Reply to: “Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies” J. Hepatol. (IF 25.7) Pub Date : 2024-03-08 Marc G. Ghany, Maria Buti, Pietro Lampertico, Hannah M. Lee
-
Pkd1l1-deficiency drives biliary atresia through ciliary dysfunction in biliary epithelial cells J. Hepatol. (IF 25.7) Pub Date : 2024-03-08 Yi Zou Lim, Min Zhu, Yunguan Wang, Tripti Sharma, Shannon Kelley, Estelle Oertling, Hao Zhu, Natasha Corbitt
-
Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Shan He, Yuru Luo, Wangge Ma, Xiaoke Wang, Chengrong Yan, Wenyang Hao, Yuan Fang, Hongyu Su, Baochang Lai, Junhui Liu, Ying Xiong, Ting Bai, Xiaoyong Ren, Enqi Liu, Hua Han, Yue Wu, Zuyi Yuan, Yidong Wang
-
Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Michaela Raab, Ersi Christodoulou, Roopesh Krishnankutty, Andreea Gradinaru, Alexander Daniel Walker, Paula Olaizola, Nicholas Thomas Younger, Anabel Martinez Lyons, Edward Joseph Jarman, Konstantinos Gournopanos, Alexander von Kriegsheim, Scott Hamilton Waddell, Luke Boulter
-
Cutting edges in the HBV genome: How RNA splicing is involved in modulating virus ultrastructure to promote infection J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Stefan Seitz, Ralf Bartenschlager
-
Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-03-07 Jennifer L. Tomlinson, Binbin Li, Jingchun Yang, Emilien Loeuillard, Hannah E. Stumpf, Hendrien Kuipers, Ryan Watkins, Danielle M. Carlson, Jessica Willhite, Daniel R. O’Brien, Rondell P. Graham, Xin Chen, Rory L. Smoot, Haidong Dong, Gregory J. Gores, Sumera I. Ilyas
-
The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Shijie GUO, Jingqiang ZENG
-
Reply to: “Familial clustering of MASLD: Rethinking strategies for population screening” J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Fahim Ebrahimi, Jonas F. Ludvigsson
-
Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria? J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Anna Di Sessa, Stefano Guarino, Giuseppina Rosaria Umano, Emanuele Miraglia del Giudice, Pierluigi Marzuillo
-
Rare monogenic causes of steatotic liver disease masquerading as MASLD J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Martijn C.G.J. Brouwers, David Cassiman
-
Autoimmune hepatitis: Mycophenolate mofetil vs. azathioprine as first-line therapy J. Hepatol. (IF 25.7) Pub Date : 2024-03-06 Cem Şimşek, Staffan Wahlin, Cumali Efe
-
Multi-omics characterization of healthy and PSC human liver – what we knew and what we have learned J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Jenny Krause, Christoph Schramm
-
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Katrine Holtz Thorhauge, Georg Semmler, Stine Johansen, Katrine Prier Lindvig, Maria Kjærgaard, Johanne Kragh Hansen, Nikolaj Torp, Camilla Dalby Hansen, Peter Andersen, Benedikt Silvester Hofer, Wenyi Gu, Mads Israelsen, Mattias Mandorfer, Thomas Reiberger, Jonel Trebicka, Maja Thiele, Aleksander Krag, the Microb-Predict Galaxy and MicrobLiver consortia
-
Multidrug-resistant bacterial infections after liver transplantation: Prevalence, impact, and risk factors J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Rosa Martin-Mateos, Laura Martínez-Arenas, Ángela Carvalho-Gomes, Laia Aceituno, Valle Cadahía, María Magdalena Salcedo, Ana Arias, Sara Lorente Pérez, Aitor Odriozola, Javier Zamora, Marino Blanes, Óscar Len, Laura Benítez, Isabel Campos-Varela, María Luisa González Diéguez, Diego Rojo Lázaro, Jesús Fortún, Antonio Cuadrado, Natalia Marcos Carrasco, Manuel Rodríguez-Perálvarez, Carmen Navascues, Emilio
-
Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Balakrishnan Chakrapani Narmada, Atefeh Khakpoor, Niranjan Shirgaonkar, Sriram Narayanan, Pauline Poh Kim Aw, Malay Singh, Kok Haur Ong, Collins Oduor Owino, Jane Wei Ting Ng, Hui Chuing Yew, Nu Soibah Binte Mohamed Nasir, Veonice Bijin Au, Reina Sng, Nivashini Kaliaperumal, Htet Htet Toe Wai Khine, Francesca Casuscelli di Tocco, Otsuka Masayuki, Shamita Naikar, Hui Xin Ng, Su Li Chia, Cindy Xin Yi
Hepatitis B surface antigen (HBsAg) loss or functional cure (FC), is considered the desirable therapeutic outcome for chronic hepatitis B (CHB) patients. However, the immune-pathological biomarkers and underlying mechanisms remain unclear. In this study we comprehensively interrogate disease-associated cell states (DACS) identified within intra-hepatic tissue and matched PBMCs from either CHB or FC
-
PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice J. Hepatol. (IF 25.7) Pub Date : 2024-02-28 Yan Yang, Jiale Wang, Jianhua Wan, Qianqian Cheng, Zenong Cheng, Xueli Zhou, Oliver Wang, Kelvin Shi, Lingxiang Wang, Bin Wang, Xiaohui Zhu, Jiaxiang Chen, Dongfeng Feng, Yang Liu, Yasmin Jahan-mihan, Ashley N. Haddock, Brandy H. Edenfield, Guang Peng, Jessica D. Hohenstein, Chantal E. McCabe, Daniel R. O'Brien, Chen Wang, Sumera I. Ilyas, Liuyan Jiang, Michael S. Torbenson, Huamin Wang, Raouf E. Nakhleh
-
Comment on “Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany” J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Renke Biallas, Ruth Zimmermann, Sandra Dudareva
-
Potential augmentation of terlipressin antidiuretic effects by gabapentinoids J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Penelope N. Markham, Jasmohan S. Bajaj, Paul J. Thuluvath, David Koch, Joseph Palumbo
-
Changing from NAFLD to MASLD: The implications for health-related quality of life data J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Ryuki Hashida, Dan Nakano, Machiko Kawaguchi, Zobair M. Younossi, Takumi Kawaguchi
-
Autoimmune hepatitis: Azathioprine or mycophenolate mofetil for inducing remission? J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Avinash Tiwari, Duncan Khanikar, Santosh Govind Rathod
-
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Peiyi Xie, Mincheng Yu, Bo Zhang, Qiang Yu, Yufei Zhao, Mengyuan Wu, Lei Jin, Jiuliang Yan, Binghai Zhou, Shuang Liu, Xiaoqiang Li, Chenhao Zhou, Xiaodong Zhu, Cheng Huang, Yongfeng Xu, Yongsheng Xiao, Jian Zhou, Jia Fan, Mien-Chie Hung, Qinghai Ye, Lei Guo, Hui Li
Immune checkpoint inhibitors (ICIs) resistance limits immunotherapy success in hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in HCC against anti-PD-1 therapy. Gene expression in HCC specimens from 10 patients accepted anti-PD-1 therapy was identified by RNA-sequencing
-
An in-depth exploration of difference and similarity between NAFLD and MASLD J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Yubo Liu, Liao Tan
-
Should MMF treatment be the first-line therapy in autoimmune hepatitis? J. Hepatol. (IF 25.7) Pub Date : 2024-02-23 Laurent Alric
-
Let’s unite Hepatology! Become an EASL member today and discover your benefits J. Hepatol. (IF 25.7) Pub Date : 2024-02-15
-
-
-
-
Use of stem cell-derived hepatocytes to model liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Josef Blaszkiewicz, Stephen A. Duncan
-
Jaundice with severe leucocytosis J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Sarah Haxhe, Pamela Baldin, Pierre Trefois, Violaine Havelange, Nicolas Lanthier
-
-
-
-
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Elisabetta Caon, Maria Martins, Harry Hodgetts, Lieke Blanken, Maria Giovanna Vilia, Ana Levi, Kessarin Thanapirom, Walid Al-Akkad, Jeries Abu-Hanna, Guido Baselli, Andrew R. Hall, Tu Vinh Luong, Jan-Willem Taanman, Michele Vacca, Luca Valenti, Stefano Romeo, Giuseppe Mazza, Massimo Pinzani, Krista Rombouts
-
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April J. Hepatol. (IF 25.7) Pub Date : 2024-02-15
-
From the Editor’s Desk... J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli
-
Reply to: “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?” J. Hepatol. (IF 25.7) Pub Date : 2024-02-15 Silvia Nardelli, Filippo Schepis, Francesco Vizzutti
-
Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding J. Hepatol. (IF 25.7) Pub Date : 2024-02-13 Jean de Ville de Goyet
-
Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition J. Hepatol. (IF 25.7) Pub Date : 2024-02-10 Yasser Fouad, Hasmik Ghazinyan, Mohamed Alboraie, Maryam Al Khatry, Hailemichael Desalegn, Fuad Al-Ali, Mortada H.F. El-Shabrawi, Ponsiano Ocama, Moutaz Derbala, Salma Barakat, Yaw Asante Awuku, Dennis Amajuoyi Ndububa, Meriam Sabbah, Waseem Hamoudi, Masolwa Ng'wanasayi, Reda Elwakil, Reidwan Ally, Said A. Al-Busafi, Almoutaz Hashim, Gamal Esmat, Gamal Shiha
-
Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis J. Hepatol. (IF 25.7) Pub Date : 2024-02-10 Samer Gawrieh, Srinivasan Dasarathy, Wanzhu Tu, Patrick S. Kamath, Naga P. Chalasani, Craig J. McClain, Ramon Bataller, Gyongyi Szabo, Qing Tang, Svetlana Radaeva, Bruce Barton, Laura E. Nagy, Vijay H. Shah, Arun J. Sanyal, Mack C. Mitchell, for The AlcHepNet Investigators, Naga Chalasani, Kavish R. Patidar, Raj Vuppalanchi, Niha Samala, Lindsey Yoder, Lauren Nephew, Vijay H. Shah, Douglas A. Simonetto
-
Reply to: ‘A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!’ J. Hepatol. (IF 25.7) Pub Date : 2024-02-10 Hyun Yang, Jeong Won Jang
-
From the experimental to the clinical: Deepening the understanding of mycophenolate mofetil combined with prednisolone therapy J. Hepatol. (IF 25.7) Pub Date : 2024-02-10 Yixuan Xu, Xiaofei Yu, Yongmei Guo